Comparable stake leader
ARCH Venture Fund XII, L.P.
SEC ownership of Neumora Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001885522.
Disclosed value leader
ARCH Venture Fund XII, L.P.
Comparable rows
50/50
Latest evidence
20 Aug 2026
- Public ticker
- NMRA on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARCH Venture Fund XII, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARCH Venture Fund XII, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
20 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001885522
- Issuer location
- Watertown, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Neumora Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARCH Venture Fund XII, L.P.
Disclosed value leader
ARCH Venture Fund XII, L.P.
Comparable rows
50/50
Latest evidence
20 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 19%
13D/G row: ARCH Venture Fund XII, L.P.
Showing 1-8 of 50 holder rows.
Quick read
ARCH Venture Fund XII, L.P. leads the comparable SEC ownership view at 19%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Fund XII, L.P.'s linked filing trail.
Comparable ownership
Top 5
ARCH Venture Fund XII, L.P.
19%
Paul L. Berns
5.1%
Invus Global Management, LLC
4.7%
K2 HealthVentures Equity Trust LLC
3.1%
FMR LLC
2.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. |
13D/G
Kristina Burow
|
19%
|
$69,289,455
33,965,419 shares
|
+$13,162 | 30 Mar 2026 |
| Paul L. Berns |
3/4/5
13D/G
Title: Executive Chair of the Board, Director
|
5.1%
from 13D/G
|
$26,224,179
8,028,282 shares
mixed-class rows
|
-$34,459 | 20 Aug 2026 |
| Invus Global Management, LLC |
13D/G
Raymond Debbane
|
4.7%
|
$16,570,753
8,497,822 shares
|
-$975,000 | 31 Mar 2026 |
| K2 HealthVentures Equity Trust LLC |
13D/G
|
3.1%
|
$11,291,383
5,790,453 shares
|
-$6,252,835 | 31 Mar 2026 |
| FMR LLC |
3/4/5
13D/G
13F
Other* · Company
|
2.2%
from 13D/G
|
$67,379,749
5,624,353 shares
|
— | 19 Sep 2023 |
| ARCH Venture Partners X, LLC |
3/4/5
10%+ Owner
|
18%
|
$66,380,119
33,847,838 shares
|
+$4,999,977 | 27 Oct 2025 |
| ARCH Venture Partners XII, LLC |
3/4/5
10%+ Owner
|
18%
|
$66,380,119
33,847,838 shares
|
+$4,999,977 | 27 Oct 2025 |
| Siren, L.L.C. |
13F
Individual
|
4.5%
|
$14,446,297
8,497,822 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$13,908,676.
Buys
$14,999,931
Insiders: 3
Sells
$1,091,255
Insiders: 4
Net
+$13,908,676
Shares: +5,155,177
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 5,747,100
Shares: 591,923
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 453,833 | $0 | $701,641 | -$701,641 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 23,387 | $0 | $82,588 | -$82,588 |
| 9-12 | 5,747,100 | 114,703 | $14,999,931 | $307,026 | +$14,692,905 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Neumora Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
AMGEN INC
Net 12M change
+$13,908,677
Latest report
20 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| AMGEN INC | 10%+ Owner | $423,716,463 | Mixed | 19 Sep 2023 | ||
| FMR LLC | Other* | $67,379,749 | Mixed | 19 Sep 2023 | ||
| Kristina Burow | Director, 10%+ Owner | $66,466,963 | +$4,999,977 | +8.1% | Mixed | 27 May 2026 |
| ARCH Venture Partners X, LLC | 10%+ Owner | $66,380,119 | +$4,999,977 | +8.1% | Mixed | 27 Oct 2025 |
| ARCH Venture Partners XII, LLC | 10%+ Owner | $66,380,119 | +$4,999,977 | +8.1% | Mixed | 27 Oct 2025 |
| Paul L. Berns | Title: Executive Chair of the Board, Director | $26,224,179 | -$34,459 | -0.13% | Mixed | 20 Aug 2026 |
| Gosebruch Henry O | President & CEO, Director | $7,065,720 | Mixed | 14 Feb 2024 | ||
| Carol Y. Suh | Chief Operating Officer | $4,488,595 | Mixed | 14 Feb 2024 | ||
| Robert A. Lenz | Head of R&D | $516,616 | Filing P/S | 18 Feb 2025 | ||
| Joshua Pinto | President & CEO, Director | $514,682 | -$21,093 | -3.9% | Mixed | 20 Aug 2026 |
| Matthew K. Fust | Director | $342,395 | Filing P/S | 27 May 2026 | ||
| David Piacquad | Director | $240,798 | Mixed | 27 May 2026 | ||
| Maykin Ho | Director | $240,798 | Mixed | 27 May 2026 | ||
| Alaa Halawa | Director | $240,798 | Mixed | 27 May 2026 | ||
| Daljit Singh Aurora | Title: Chief Operating and Development Officer | $77,751 | -$1,030,583 | -93% | Filing P/S | 20 Aug 2026 |
| Michael Lee Milligan | Title: Chief Financial Officer & Principal Accounting Officer | $74,986 | -$5,119 | -6.4% | Filing P/S | 20 Aug 2026 |
| Jason Duncan | Title: Chief Legal and Administrative Officer | Mixed | 20 Aug 2026 |
Recent insider transactions for Neumora Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $33,600 | $1.60 | -21,055 | 0 | 21 Aug 2026 | See footnote |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 21,055 | 21,055 | 21 Aug 2026 | See footnote | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -29.7% | $32,780 | $1.59 | -20,553 | 48,750 | 21 Aug 2026 | Direct |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 42.2% | 20,553 | 69,303 | 21 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -18.2% | -21,055 | 94,798 | 21 Aug 2026 | See footnote | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -18.8% | -20,553 | 88,974 | 21 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $101,000 | $1.51 | -66,711 | 0 | 20 Aug 2026 | See footnote |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 66,711 | 66,711 | 20 Aug 2026 | See footnote | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -58.2% | $102,587 | $1.51 | -67,741 | 48,750 | 20 Aug 2026 | Direct |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 139% | 67,741 | 116,491 | 20 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Award | 200,000 | 200,000 | 20 Aug 2026 | Direct | |||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -100% | -66,711 | 0 | 20 Aug 2026 | See footnote | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -38.2% | -67,741 | 109,527 | 20 Aug 2026 | Direct | ||
| Paul L. Berns | NMRA | Stock Option (Right to Buy) | Award | 500,000 | 500,000 | 20 Aug 2026 | Direct | |||
| Jason Duncan | NMRA | Stock Option (Right to Buy) | Award | 375,000 | 375,000 | 20 Aug 2026 | Direct | |||
| Michael Lee Milligan | NMRA | Stock Option (Right to Buy) | Award | 175,000 | 175,000 | 20 Aug 2026 | Direct | |||
| Joshua Pinto | NMRA | Stock Option (Right to Buy) | Award | 500,000 | 500,000 | 20 Aug 2026 | Direct | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $50,888 | $1.65 | -30,918 | 0 | 19 Aug 2026 | See footnote |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 30,918 | 30,918 | 19 Aug 2026 | See footnote | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -38.9% | $51,029 | $1.65 | -31,000 | 48,750 | 19 Aug 2026 | Direct |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 63.6% | 31,000 | 79,750 | 19 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -40.7% | -30,918 | 45,026 | 19 Aug 2026 | See footnote | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -57% | -31,000 | 23,367 | 19 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $55,486 | $1.59 | -34,987 | 0 | 18 Aug 2026 | See footnote |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 34,987 | 34,987 | 18 Aug 2026 | See footnote | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -41.2% | $54,137 | $1.58 | -34,162 | 48,750 | 18 Aug 2026 | Direct |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 70.1% | 34,162 | 82,912 | 18 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -31.5% | -34,987 | 75,944 | 18 Aug 2026 | See footnote | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -48.2% | -34,162 | 36,635 | 18 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $82,783 | $1.50 | -55,016 | 0 | 17 Aug 2026 | See footnote |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 55,016 | 55,016 | 17 Aug 2026 | See footnote | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -65.3% | $137,352 | $1.50 | -91,690 | 48,750 | 17 Aug 2026 | Direct |
| Daljit Singh Aurora | NMRA | Common Stock | Options Exercise | 69.7% | 57,670 | 140,440 | 17 Aug 2026 | Direct | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -100% | -55,016 | 0 | 17 Aug 2026 | See footnote | ||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Options Exercise | -100% | -57,670 | 0 | 17 Aug 2026 | Direct | ||
| Kristina M. Burow | NMRA | Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 27 May 2026 | Direct | |||
| Matthew K. Fust | NMRA | Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 27 May 2026 | Direct | |||
| David Piacquad | NMRA | Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 27 May 2026 | Direct | |||
| Alaa Halawa | NMRA | Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 27 May 2026 | Direct | |||
| Maykin Ho | NMRA | Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 27 May 2026 | Direct | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -6.93% | $21,917 | $3.56 | -6,165 | 82,770 | 17 Feb 2026 | Direct |
| Joshua Pinto | NMRA | Common Stock | Sale | -9.36% | $21,093 | $3.54 | -5,967 | 57,783 | 17 Feb 2026 | Direct |
| Paul L. Berns | NMRA | Common Stock | Sale | -0.13% | $34,459 | $3.51 | -9,819 | 7,395,185 | 17 Feb 2026 | Direct |
| Michael Lee Milligan | NMRA | Common Stock | Sale | -6.39% | $5,119 | $3.56 | -1,436 | 21,034 | 17 Feb 2026 | Direct |
| Michael Lee Milligan | NMRA | Stock Option (Right to Buy) | Award | 350,000 | 350,000 | 08 Jan 2026 | Direct | |||
| Daljit Singh Aurora | NMRA | Stock Option (Right to Buy) | Award | 750,000 | 750,000 | 08 Jan 2026 | Direct | |||
| Jason Duncan | NMRA | Stock Option (Right to Buy) | Award | 750,000 | 750,000 | 08 Jan 2026 | Direct | |||
| Joshua Pinto | NMRA | Stock Option (Right to Buy) | Award | 1,200,000 | 1,200,000 | 08 Jan 2026 | Direct | |||
| Paul L. Berns | NMRA | Stock Option (Right to Buy) | Award | 1,650,000 | 1,650,000 | 08 Jan 2026 | Direct | |||
| Daljit Singh Aurora | NMRA | Common Stock | Sale | -100% | $307,026 | $2.68 | -114,703 | 0 | 11 Nov 2025 | See footnote |
* marks a reported price that did not pass the local price check.